Maxcyte (MXCT) closed at $1.13 on November 10, 2026, down 13.1% from the previous close, on volume of 3,982,566 shares (30-day average 1,300,761).
Data as of November 10, 2026.
10-Nov-2026
MaxCyte falls after $151.8M deal to buy Akron Bio for cash and stock
Seeking Alpha News (Tue, 10-Nov 12:40 PM ET)
MaxCyte Reports Strong Third-Quarter Revenue Growth and Narrower Loss
TipRanks (Tue, 10-Nov 8:46 AM ET)
MaxCyte beats Q3 EPS and revenue estimates, issues FY revenue guidance above consensus
Seeking Alpha News (Tue, 10-Nov 6:06 AM ET)
Globe Newswire (Tue, 10-Nov 6:01 AM ET)
Globe Newswire (Tue, 10-Nov 6:00 AM ET)
MaxCyte to Participate in Three Upcoming Investor Conferences
Globe Newswire (Wed, 28-Oct 8:05 AM ET)
MXCT jumps after preliminary Q3 revenue points to a guidance raise to about $34 million
Market Chameleon (Wed, 14-Oct 5:54 AM ET)
MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
Globe Newswire (Wed, 14-Oct 8:05 AM ET)
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
Globe Newswire (Wed, 23-Sep 8:05 AM ET)
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 11-Sep 4:30 PM ET)
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Maxcyte trades on the NASDAQ stock market under the symbol MXCT.
As of November 10, 2026, MXCT stock price declined to $1.13 with 3,982,566 million shares trading.
MXCT has a beta of 1.62, meaning it tends to be more sensitive to market movements. MXCT has a correlation of 0.07 to the broad based SPY ETF.
MXCT has a market cap of $116.62 million. This is considered a Micro Cap stock.
Last quarter Maxcyte reported $7 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $797,080 and exceeded earnings estimates by $.02.
In the last 3 years, MXCT traded as high as $5.55 and as low as $.64.
The top ETF exchange traded funds that MXCT belongs to (by Net Assets): VTI, VXF, VHT, BUSM.
MXCT has underperformed the market in the last year with a price return of -21.5% while the SPY ETF gained +12.9%. MXCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -4.2% and -25.2%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
MXCT support price is $1.21 and resistance is $1.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MXCT shares will trade within this expected range on the day.